Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3125-3128

  Ustuner, Zeki ^a   Meltem Akay, O ^a   Keskin, Muge ^a   Kuş, Esin ^a   Bal, Cengiz ^a   Gulbas, Zafer ^b  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

^b Anadolu Saglik Merkezi Hospital   (Turkey)

Author keywords

Bevacizumab; Coagulation; Colorectal cancer; Thrombelastography

Indexed keywords

BEVACIZUMAB; D DIMER; FIBRINOGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIAGNOSTIC EQUIPMENT; EPISTAXIS; HUMAN; LABORATORY TEST; LUNG EMBOLISM; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RECTUM HEMORRHAGE; THROMBOCYTE COUNT; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; METHODOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; THROMBELASTOGRAPHY;

EID: 84876541835     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0274-0     Document Type: Article

References (15)

1. Roddy JVF, Partridge SM, Rockey ML, Pruemer JM, Guo JJ, Desai SJ, et al. Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab- based chemotherapy and erythropoietin stimulating agents. Am J Clin Oncol. 2010;33:36-42.
2. Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol. 2009;22(1):115-28.
3. Blowers E, Hall K. Adverse events in bevacizumab and chemotherapy:patient management. Br J Nurs. 2009;18(7):424-8.
4. Elice F, Rodeghiero F. Bleeding complications of antiangiogenetic therapy:pathogenetic mechanism and clinical impact. Thromb Res. 2010;125(Suppl. 2):S55-7.
5. Hartert H. Blutgerinnungsstudien mit der thrombelatographie, einem neuen untersuchungs verfahren. Klinische Wochenschrift. 1948;26:577-83.
6. Traverso CI, Caprini JA, Arcelus JI. The normal thromboelastogram and its interpretation. Semin Thromb Hemost. 1995;21(Suppl 4):7-13.
7. Donahue SM, Otto CM. Thrombelastography: a tool for measuring hypercoagulability, hypocoagulability, and fibrinolysis. J Vet Emerg Crit Care. 2005;15(1):9-16.
8. Schobersberger W, Mittermayr M, Fries D, Innerhofer P, Klingler A, Faulhaber M, et al. Changes in blood coagulation of arm and leg veins during a simulated long-haul flight. Thromb Res. 2007;119:293-300.
9. Sorenson B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. J Thromb Haemost. 2002;1:551-8.
10. Akay OM, Ustuner Z, Canturk Z, Mutlu FS, Gulbas Z. Laboratory investigation of hypercoagulability in cancer patients using rotation thrombelastography. Med Oncol. 2008;26(3):358-64.
11. Kabbinavar F, Hurwitz HI, Fehrenbacher L. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-5.
12. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer. High incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol. 2005;23:2574-6.
13. Johson DH, Fehrenbacher L, Novotny WF, Herbst RS, Neumanitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;350:2335-42.
14. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009;27:4865-73.
15. Mallett SV, Cox DJA. Thrombelastography. Br J Anaesth. 1992;69:307-13.